Progress of Adjuvant Therapy for Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

Xu Binghe

Corresponding author：

Keywords：

乳腺癌; 辅助治疗

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： Xu Binghe. Progress of Adjuvant Therapy for Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(1): 6-8. doi: Copy

1.	Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positivenode breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B15 [J]. J Clin Oncol, 1990; 8(9)∶1483.
2.	Early Breast Cancer Trialists’Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials [J]. Lancet, 1998; 352(9132)∶930.
3.	Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high risk node negative breast cancer patients and a natural history followup study in low risk node negative patients: first results of Intergroup trial in 0102 [J]. Proc Am Soc Clin Oncol, 1998; 17∶2a.
4.	Henderson IC, Berry D, Demetri G, et al. Improved diseasefree (dfs) and overall survival (os) from the addition of sequentiall paclitaxel (t) but not from the escalation of doxorubicin (a) dose level in the adjuvant chemotherapy of patients (pts) with nodepositive primary breast cancer (bc) [J] . Proc Am Soc Clin Oncol, 1998； 17∶390a.
5.	Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph nodenegative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B14 randomized trial [J]. J Natl Cancer Inst, 2001; 93(9)∶684.
6.	Fisher B, Redmond C, LegaultPoisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positivenode breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B16 [J]. J Clin Oncol, 1990; 8(6)∶1005.
7.	Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph nodenegative, estrogen receptorpositive breast cancer [J]. J Natl Cancer Inst, 1997; 89(22)∶1673.
8.	Williams NR, Houghton J, Baum M. Conrentienal adjuvant hormonal therapy[A]. In: Bonadonna G, Hortobagyi GN, Gianni AH, eds. 2nd. London: Martin Dunitz, 2001 ∶151-160.
9.	Albain KS, Green SJ, Racsin PM, et al. Adjuvant chemohomonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG8814) [J]. Proc Am Soc Clin Oncol, 2002； 21∶37a.
10.	Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer [J]. J Clin Oncol, 2003; 21(6)∶976.

1. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positivenode breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B15 [J]. J Clin Oncol, 1990; 8(9)∶1483.
2. Early Breast Cancer Trialists’Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials [J]. Lancet, 1998; 352(9132)∶930.
3. Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high risk node negative breast cancer patients and a natural history followup study in low risk node negative patients: first results of Intergroup trial in 0102 [J]. Proc Am Soc Clin Oncol, 1998; 17∶2a.
4. Henderson IC, Berry D, Demetri G, et al. Improved diseasefree (dfs) and overall survival (os) from the addition of sequentiall paclitaxel (t) but not from the escalation of doxorubicin (a) dose level in the adjuvant chemotherapy of patients (pts) with nodepositive primary breast cancer (bc) [J] . Proc Am Soc Clin Oncol, 1998； 17∶390a.
5. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph nodenegative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B14 randomized trial [J]. J Natl Cancer Inst, 2001; 93(9)∶684.
6. Fisher B, Redmond C, LegaultPoisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positivenode breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B16 [J]. J Clin Oncol, 1990; 8(6)∶1005.
7. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph nodenegative, estrogen receptorpositive breast cancer [J]. J Natl Cancer Inst, 1997; 89(22)∶1673.
8. Williams NR, Houghton J, Baum M. Conrentienal adjuvant hormonal therapy[A]. In: Bonadonna G, Hortobagyi GN, Gianni AH, eds. 2nd. London: Martin Dunitz, 2001 ∶151-160.
9. Albain KS, Green SJ, Racsin PM, et al. Adjuvant chemohomonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG8814) [J]. Proc Am Soc Clin Oncol, 2002； 21∶37a.
10. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer [J]. J Clin Oncol, 2003; 21(6)∶976.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Progress of Adjuvant Therapy for Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content